Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

July 31, 2011

Conditions
Systemic SclerosisScleroderma
Interventions
DRUG

treprostinil diethanolamine

oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)

DRUG

placebo

Trial Locations (30)

10021

The Hospital for Special Surgery, New York

11042

North Shore-LIJ Health System, Lake Success

15261

University of Pittsburgh, Pittsburgh

20007

Georgetown University, Washington D.C.

21224

Johns Hopkins University - Division of Rheumatology, Baltimore

29425

Medical University of South Carolina, Charleston

35294

University of Alabama - Arthritis Clinical Intervention Program, Birmingham

43614

University of Toledo, Toledo

44195

Cleveland Clinic Foundation, Cleveland

46202

University of Indiana School of Medicine, Indianapolis

48106

University of Michigan Scleroderma Program, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60611

Northwestern University - Feinberg School of Medicine, Chicago

77030

University of Texas - Houston, Houston

80045

Denver Medical Center, Aurora

84132

University of Utah, Salt Lake City

85259

Mayo Clinic Scottsdale, Scottsdale

90095

UCLA, Los Angeles

94304

Stanford University School of Medicine/Palo Alto VA Health Care System, Palo Alto

98111

Virginia Mason Medical Center, Seattle

06030

University of Connecticut Health Center, Farmington

02118

Boston University School of Medicine, Boston

08903

UMDNJ Clinical Research Center, New Brunswick

B3H4K4

Dalhousie University - QEII Health Science Center, Halifax

N6A4V2

St Joseph's Health Care, London

H3T1E2

McGill University, Montreal

L9 7AL

Clinical Sciences Center - University Hospital, Liverpool

NW32QG

Royal Free Hospital - Center for Rheumatology, London

M139PT

Salford Royal Hospital, Manchester

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY